Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) may have lost US$12m in value but insiders who invested last year have seen gains of around US$258k to date

Insiders who bought Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) stock lover the last 12 months are probably not as affected by last week’s 13% loss. Reason being, despite the recent loss, insiders original purchase value of US$158k is now worth US$416k.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

See our latest analysis for Reviva Pharmaceuticals Holdings

The Last 12 Months Of Insider Transactions At Reviva Pharmaceuticals Holdings

Over the last year, we can see that the biggest insider purchase was by Chief Financial Officer Narayan Prabhu for US$83k worth of shares, at about US$1.66 per share. Even though the purchase was made at a significantly lower price than the recent price (US$4.04), we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

Reviva Pharmaceuticals Holdings insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

Reviva Pharmaceuticals Holdings is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Does Reviva Pharmaceuticals Holdings Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 17% of Reviva Pharmaceuticals Holdings shares, worth about US$16m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Does This Data Suggest About Reviva Pharmaceuticals Holdings Insiders?

The fact that there have been no Reviva Pharmaceuticals Holdings insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. Insiders own shares in Reviva Pharmaceuticals Holdings and we see no evidence to suggest they are worried about the future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For example, Reviva Pharmaceuticals Holdings has 6 warning signs (and 2 which are potentially serious) we think you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

What are the risks and opportunities for Reviva Pharmaceuticals Holdings?

NasdaqCM:RVPH

Reviva Pharmaceuticals Holdings

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases.Show more

View Full Analysis

Risks

• Makes less than USD$1m in revenue ($0)

• Does not have a meaningful market cap ($86M)

• Shareholders have been diluted in the past year

• Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report

Further research on
Reviva Pharmaceuticals Holdings

ValuationFinancial HealthInsider TradingManagement Team

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.